Technology

The Sonnet F_HAB Mechanism of Action

Our modular F_HAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.

Technology Backed by Industry Expertise

Sonnet’s deep knowledge of immune biology is complemented by our extensive drug discovery and development expertise.

A Modular Drug Development Platform

Our Fully Human Albumin-Binding (F_HAB) construct is the foundation of a fully modular technology that enables the design of single or bifunctional biologic compounds that target albumin, which binds to FcRn, GP60 and SPARC.

Compatibility with many biologic drug classes, including interleukins, growth factors, peptides and vaccines
Enhanced pharmacokinetics
Targeted, directed activity for tumor selectivity
Increased in vivo efficacy
Single- or bi-specific mechanisms of action

Platform Overview

Human Serum Albumin (HSA) is naturally present in the bloodstream and is the predominant protein in blood plasma. Albumin accumulates at sites of inflammation, including tumors. Following administration, Sonnet’s F_HAB-conjugated therapies bind to and “hitch-hike” on patients’ endogenous HSA for transport to the target tissues.

New Page_SON1210_Sarcoma Oncology Center Logo

A Customizable, Single Domain Antibody Fragment Platform

We are actively leveraging our proprietary platform to develop a pipeline of single- and bi-functional therapies capable of stimulating and/or blocking immune-modulating targets.

About Our Platform

Dedicated to Improving Immunotherapy Response Rates

Our versatile platform has shown to improve the delivery of the active drug(s) to the tumor, as well as to help overcome past challenges with cytokine-based treatments, which are essential for improving immunotherapy response rates.

Established Preclinical Proof-of-Concept

Our albumin-binding ScFv has demonstrated up to 10x increase in serum half-life and improved tumor penetration, as well as improved antitumor activity as a result of immune-modulating cytokines delivered via Sonnet’s albumin-binding scaffold.

Research Publications

At Sonnet BioTherapeutics, we offer a selection of publications to provide readers with more information on our current research efforts in immunotherapy.

View Publications